Research and Development Center, Santen Pharmaceutical Co. Ltd, Ikoma-shi, Nara, Japan. hisashi.tajima@santen.co.jp
Abstract:
Optimization from compound 4a, having intramolecular S-O nonbonded interaction, led to discover compounds 4m and 4n. They were highly active in vitro (VEGF induced HUVEC proliferation assay) and showed efficacies in three disease models in vivo (cancer, RA, AMD).